RxDoctor Payments Data

Wesley Howell, PA

Physician Assistant · Carbondale, ILNPI 1528508074

Payments from drug & device makers

$1,302in general payments, 2019–2025

Across 52 payments — averaging $25.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Antares Pharma, Inc.$299
  • Endo Pharmaceuticals Inc.$254
  • Astellas Pharma US Inc$189
  • Myovant Sciences Inc.$113
  • Laborie Medical Technologies Corp.$85
  • Sumitomo Pharma America, Inc.$66
  • plus $297 from 9 others

What the payments were for

  • Food & beverage$1,18491%
  • Education$1189%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,302 in reported general payments places this provider in the 75th percentile of 3,912 physician assistant providers in Illinois.

See all physician assistant providers in Illinois

Medicare billing

Part B allowed, 2024
$97,167
Medicare patients
542
Services billed
2,314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron254$191,957
MyrbetriqMirabegron160$110,363
XyostedTestosterone Enanthate63$40,124
Testosterone46$27,340
Testosterone Cypionate282$13,797
Tadalafil53$10,098
Mirabegron ErMirabegron14$9,637
Tamsulosin Hcl523$7,685
Trospium Chloride ErTrospium Chloride52$5,738
Solifenacin Succinate57$4,757
Fesoterodine Fumarate ErFesoterodine Fumarate35$3,911
Oxybutynin Chloride ErOxybutynin Chloride135$3,163
Dutasteride123$3,059
Silodosin32$3,045
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst92$3,010

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$66$191,957254 claims
Astellas Pharma US IncMyrbetriq$189$110,363160 claims
Antares Pharma, Inc.Xyosted$299$40,12463 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,912 physician assistant providers in Illinois.

Other physician assistant in Carbondale

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →